Results 311 to 320 of about 178,943 (330)

Human Apolipoprotein A-I Deficiency

2010
Our purpose is to review the characteristics of probands described with familial apolipoprotein (apo) A-I deficiency. Decreased plasma high density lipoprotein (HDL) cholesterol levels (
Ernst J. Schaefer, Raul D. Santos
openaire   +1 more source

Apolipoprotein A-I: Deficiency in Tangier Disease

1988
The near absence of apolipoprotein A-I (apo A-I) characterizes Tangier disease. However, no unequivocal evidence of a molecular defect in apo A-I or apo A-I gene has been established (1-13). It could signify that the molecular defect is not necessarily the same in every patient.
M F, Dumon, M, Clerc, M, Clerc
openaire   +2 more sources

Repeated helical pattern in apolipoprotein-A-I

Nature, 1977
THE binding of lipids into globules by the serum lipid-binding proteins depends on the unique structures of these proteins. Many have a high α helix content1–4 which is enhanced by the binding of lipid, and their amino acid sequences5–8 suggest that the helices are often ‘amphipathic’ with a long hydrophobic face buried in the lipid surface9,10 and an ...
openaire   +2 more sources

The promise of apolipoprotein A-I mimetics

Current Opinion in Endocrinology, Diabetes & Obesity, 2010
Synthetic high-density lipoprotein (HDL) and apolipoprotein (apo) A-I mimetic peptides emulate many of the atheroprotective biological functions attributed to HDL and can modify atherosclerotic disease processes. Administration of these agents as HDL replacement or modifying therapy has tremendous potential of providing new treatments for ...
openaire   +2 more sources

Human Apolipoprotein A-I Mutants

2010
Forty-six mutations in the human APOA1 gene are listed in the Human Gene Mutation Database. Eighteen mutations cause a Low-HDL phenotype associated with an extremely variable atherosclerosis burden and coronary risk, illustrating that the plasma HDL level per se does not necessarily reflect the atheroprotective potential of these lipoproteins, and ...
openaire   +1 more source

Pharmacology of apolipoprotein A-l

Current Opinion in Lipidology, 1997
The role of HDL and its main protein component the apolipoprotein A-I as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms.
openaire   +2 more sources

Apolipoprotein E gene expression is reduced in apolipoprotein A-I transgenic mice

Molecular and Cellular Biochemistry, 2000
The levels of plasma apolipoprotein (apo) E, an anti-atherogenic protein involved in mammalian cholesterol transport, were found to be 2-3 fold lower in mice over-expressing human apoA-I gene. ApoE is mainly associated with VLDL and HDL-size particles, but in mice the majority of the apoE is associated with the HDL particles.
openaire   +2 more sources

Familial Apolipoprotein A-I Deficiency

2016
Apolipoprotein (apo) A-I is the key structural protein of high-density lipoprotein (HDL) and is necessary for sustaining the circulating level of HDL. It has also been studied extensively for its role in mediating many of the antiatherosclerotic and antithrombotic properties of HDL.
openaire   +1 more source

[Familial apolipoprotein A-I variants].

Nihon rinsho. Japanese journal of clinical medicine, 2000
Apolipoprotein (apo) A-I is the major apolipoprotein of HDL and is a single polypeptide chain with 243 amino acid residues. Familial apo A-I deficiency is a rare metabolic disorder of which 13 cases have been characterized at the molecular level. However, in subjects with apo A-I deficiency, coronary artery disease is not always present.
openaire   +1 more source

Synthesis and secretion of apolipoprotein A-I

Biochemical Society Transactions, 1993
CALANDRA BUONAURA, Sebastiano, TARUGI, Patrizia Maria   +1 more
openaire   +2 more sources